BioWin

Wonder who’s pitching at HealthTech Investor Summit this December? Or which European investors will be listening in? On the dedicated HTIS website, you’ll find both, plus the speakers and program. 👉 https://lnkd.in/egvP87GQ

Member news! NOVADIP Biosciences S.A. reports promising interim results from its first-in-human proof-of-concept trial with NVDX3, a new game changer in the bone field. At six months post-grafting surgery with NVDX3, x-rays demonstrate that 90% of patients have reached or are steadily progressing towards complete bone healing. “We need more options to improve outcomes in bone healing, particularly for patients with co-morbidities like advanced age, diabetes and smoking,” said Philipp Leucht, MD, PhD, Vice Chair of Research, Department of Orthopedic Surgery at NYU Grossman School of Medicine. “These interim results suggest that NVDX3 may have the potential to address this unmet need.” 👉 Read the full release: https://lnkd.in/eHaizEfA

When innovators get together, good things happen. That was the case last Tuesday at our Advanced Therapies in Belgium event. We were inspired by the incredible industry leaders looking to advance the development and accessibility of next-generation therapies for patients. Collaboration between academia, industry, government, and patient associations is crucial to bringing these advanced therapies to market. Belgium has all the ingredients to become a global leader in this field, but we must work together! Key event highlights: 250+ ATMP experts from Belgium and key international stakeholders  175+ organisations, including startups, hospitals, universities & companies.  420+ partnering requests, highlighting interest in collaborative innovation. 280+ scheduled meetings, with plenty of potential partnerships ahead. Thank you to our sponsors, exhibitors, speakers, pitchers, supporters and participants! And a huge thank you to all of the strategic sponsors who made the event possible, including: UCB, Thermo Fisher Scientific, Aseptic Technologies, Johnson & Johnson, Deloitte, Wallonia Export & Investment Agency

💥They will be pitching at Advanced Therapies in Belgium tomorrow, 15 October, in Namur. Come and listen to them!

€80 billion by 2032—that’s the projected global value for ATMPs. But reaching that milestone will require collaboration. The event, Advanced Therapies in Belgium, presents such an occasion, offering a space for innovative ideas and featuring speakers from the forefront of Belgian and international ATMP innovation. Read this article featuring insights from Daniel Gibson (Cell and Gene Therapy Catapult), Kristina Levan (ATMP Sweden) and Sylvie Ponchaut (BioWin). 👉 https://lnkd.in/eMJrSjdY

Nyxoah at an important stage: the Belgian medtech has raised $27 million from a U.S. investor and is waiting for FDA approval by year’s end to begin marketing its Genio implant in the U.S. Olivier Taelman, CEO of Nyxoah, commented: “After relocating to the United States with my family this past summer, this investment reinforces our United States focus, builds on our compelling DREAM pivotal study data presented at the International Surgical Sleep Society (ISSS) congress and strengthens our financial position, providing additional opportunities as we are preparing for the launch of Genio® in the United States.” 👉 Read the full release: https://lnkd.in/g5fwAyWt

Great news for Belgian biotech! Kurma Partners, which recently invested €93 million in PANTERA — an IBA and SCK CEN joint-venture — is launching its largest venture capital investment fund to date and sees Belgium as a key market. They aim to raise over €250 million by the final closing in 2025. “Belgium, with its many serial entrepreneurs and renowned academics, is one of Europe's most dynamic biotech regions", said Rémi Droller, Managing partner de Kurma Partners. With Biofund IV, the name given to the new fund, Kurma plans to make between 16 and 20 new investments in European biotech companies. 👉 Read the full news: https://lnkd.in/e5d4jvNc

Thermo Fisher Scientific is one of the sponsors and also among the selected pitchers of our Advanced Therapies in Belgium event, bringing together 200+ industry experts this October in Namur.  During the event, Thermo Fisher Scientific will moderate pitch sessions where innovators of next-generation therapies can present their ideas to potential partners and experts, opening doors for growth and collaboration. They will also present their own pitch, focusing on automation and process optimisation. "Join us to discover how Thermo Fisher Scientific aims to be your trusted partner in the dynamic field of Cell & Gene Therapy. During this session, we will explore collaboration opportunities where our dedicated R&D teams can work side by side with you to automate and close your processes, ensuring you meet all regulatory requirements. By attending, you will learn how our tailored solutions can enhance efficiency, reduce costs, and ensure consistent manufacturing workflows. Our ultimate goal is to help you accelerate your process development and bring your therapies to market as quickly as possible. Engage with us to find out how we can support your journey towards innovative and effective Cell & Gene Therapies". Interested? Register here: https://lnkd.in/g8CyafGD MEDVIA, BioWin

Looking back at an outstanding day for health tech in Belgium. On September 19, lifetech.brussels, MEDVIA, and BioWin joined forces to host Health on Stage .be, a national matchmaking event that brought together over 25 Belgian healthcare organisations. The day featured discussions on healthcare challenges, innovative solutions, AI, medical devices, home hospitalisation, and more—all with one goal in mind: bringing health and innovation professionals closer together to improve care accessibility and quality. Catch the key takeaways and what's next in this article (FR) by Vincent Liévin. 👉 https://lnkd.in/ercBBjiY

There’s just two weeks to go until Advanced Therapies in Belgium – Mark your calendars and get ready to meet some amazing companies and organisations! Who are you most excited to connect with? Join 200+ industry experts this October: https://lnkd.in/g8CyafGD